We recently compiled a list of the 12 Stocks Under $10 With High Upside Potential. In this article, we are going to take a ...

In this article, we are going to take a look at where ImmunityBio, Inc. (NASDAQ:IBRX) stands against the other stocks under $10 with high upside potential. Small-cap stocks in the U.S. have ...

ImmunityBio (IBRX) announced U.S. Urology Partners, one of the nation’s largest independent providers of urology and related specialty ...

Private Advisor Group LLC trimmed its position in ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) by 75.4% during the 4th ...

CULVER CITY, Calif., March 13, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation’s ...

Despite Anktiva's potential, IBRX remains a "sell" due to operational, competitive, and financial challenges outweighing its prospects. ImmunityBio markets Anktiva, a "novel IL-15 receptor ...

ImmunityBio, Inc. , a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation's largest independent providers of urology and related specialty services, is one of the ...

ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage biotechnology company developing therapies and vaccines that support the natural immune system to defeat cancers and infectious diseases.

Latest data shows the largest indicative borrow rate increases among liquid option names include: Azul (AZUL) 69.46% +4.74, Direxion Daily ...